Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,604 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
As per attachment
Interim / Quarterly Report Classification · 92% confidence The document is a Board Meeting outcome announcing the audited financial results (quarter and year ended March 31, 2026), including full P&L, balance sheet and cash flow statements, auditors’ report and certifications, together with dividend recommendation and AGM date. It is not the full statutory Annual Report (10-K) but a standalone regulatory announcement of quarterly/annual audited results under SEBI LODR Reg.33. It thus constitutes the comprehensive interim/quarterly report rather than a brief earnings release or mere publication notice. FY 2026
2026-05-13 English
Record Date
Interim / Quarterly Report Classification · 89% confidence The document is a formal ‘Outcome of the Board Meeting’ notice filed under Indian LODR, but it goes beyond a brief announcement by including the full audited financial statements (P&L, balance sheet, cash flows, notes) for the quarter and year ended 31 March 2026. This constitutes substantive financial data and analysis for a period shorter than a full fiscal year (quarterly and year‐to‐date results), not merely an earnings headline or an Annual Report. Therefore, it should be classified as an Interim/Quarterly Report. FY 2026
2026-05-13 English
outcome of Meeting
Interim / Quarterly Report Classification · 92% confidence The document is a regulatory filing under SEBI LODR Regulation 33 consisting of the full audited financial statements and detailed quarterly and annual results (income statement, assets & liabilities, cash flows) for the quarter and year ended March 31, 2026. It contains substantive financial data beyond mere highlights or a notice of report publication, fitting the definition of an Interim/Quarterly Report rather than an earnings teaser or annual report. Therefore, it should be classified as an IR (Interim/Quarterly Report). FY 2026
2026-05-13 English
outcome of meeting
Interim / Quarterly Report Classification · 92% confidence The document is the outcome of a Board meeting filed under Regulation 33 of the LODR, containing full audited financial results (P&L, assets and liabilities, cash flows) for the quarter and year ended 31 March 2026. It is not merely an earnings highlights release (ER) and not the company’s full Annual Report (10-K) with MD&A and governance sections, nor simply an announcement of publication (RPA). It is the detailed quarterly/annual statutory financial report submitted to exchanges, fitting the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-13 English
Dividend
Regulatory Filings
2026-05-13 English
Outcome of Meeting
Earnings Release Classification · 87% confidence The document is a formal letter to stock exchanges detailing the Outcome of the Board Meeting held on 13 May 2026, enclosing the Approved Audited Financial Statements & Results (Standalone and Consolidated) for the quarter and year ended 31 March 2026. It is an initial statutory announcement of periodical financial results (including P&L, balance sheet, cash flows, dividend recommendation, and AGM details) under Regulation 33 of LODR, not a full Annual Report or proxy statement. This matches the definition of an Earnings Release (ER). FY 2026
2026-05-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.